PT  - JOURNAL ARTICLE
AU  - Bolcaen, Julie
AU  - Gizawy, Mohamed A.
AU  - Terry, Samantha Y.A.
AU  - Paulo, António
AU  - Cornelissen, Bart
AU  - Korde, Aruna
AU  - Engle, Jonathan
AU  - Radchenko, Valery
AU  - Howell, Roger W.
TI  - Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy
AID  - 10.2967/jnumed.122.265039
DP  - 2023 Sep 01
TA  - Journal of Nuclear Medicine
PG  - 1344--1351
VI  - 64
IP  - 9
4099  - http://jnm.snmjournals.org/content/64/9/1344.short
4100  - http://jnm.snmjournals.org/content/64/9/1344.full
SO  - J Nucl Med2023 Sep 01; 64
AB  - Auger electron (AE) radiopharmaceutical therapy (RPT) may have the same therapeutic efficacy as α-particles for oncologic small disease, with lower risks of normal-tissue toxicity. The seeds of using AE emitters for RPT were planted several decades ago. Much knowledge has been gathered about the potency of the biologic effects caused by the intense shower of these low-energy AEs. Given their short range, AEs deposit much of their energy in the immediate vicinity of their site of decay. However, the promise of AE RPT has not yet been realized, with few agents evaluated in clinical trials and none becoming part of routine treatment so far. Instigated by the 2022 “Technical Meeting on Auger Electron Emitters for Radiopharmaceutical Developments” at the International Atomic Energy Agency, this review presents the current status of AE RPT based on the discussions by experts in the field. A scoring system was applied to illustrate hurdles in the development of AE RPT, and we present a selected list of well-studied and emerging AE-emitting radionuclides. Based on the number of AEs and other emissions, physical half-life, radionuclide production, radiochemical approaches, dosimetry, and vector availability, recommendations are put forward to enhance and impact future efforts in AE RPT research.